ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research American College of Cardiology

In this interview, John McMurray, MD, and Alison Bailey, MD, with Nosheen Reza, MD, discuss the use of mineralocorticoid-receptor antagonist and outcomes in heart failure with reduced ejection fraction.

New analyses highlight the atrial fibrillation subpopulations with potential to progress to major morbidity outcomes and permit a reevaluation of the benefits of rhythm control for these endpoints and need for early restoration of rhythm control. In this interview, Sanjeev Saksena MBBS, MD, FACC, and Andrea M. Russo MD, FACC, with Arav Jhand, MD, discuss reinterpreting the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) study in 2020.

Given the low cost of coronary artery calcium (CAC) testing and the high likelihood that it will change management of the patient, the cost-effectiveness of CAC testing is robust due to better and more accurate targeting of intermediate risk patients to statin and aspirin therapy and promotion of adherence to those therapies. In this interview, Matthew Budoff, MD; C. Noel Bairey Merz, MD, FACC; and Poonam Velagapudi, MD, MS, discuss the cost-effectiveness of CAC testing and statin therapy.

ACCEL Associate Editors Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, and Andrew Kates, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD, FACC, about their top takeaways from 2020 in electrophysiology and general cardiology.

ACCEL Associate Editors Clyde W. Yancy, MD, FACC, and C. Noel Bairey Merz, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD, FACC, about their top takeaways from 2020 in heart failure and prevention.

ACCEL Associate Editors Christopher M. Kramer, MD, FACC, and Deepak L. Bhatt, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD FACC, about their top takeaways from 2020 in imaging and interventional cardiology.